Intraocular Melanoma Completed Phase 2 Trials for Sargramostim (DB00020)

Also known as: Intraocular melanoma NOS

IndicationStatusPhase
DBCOND0028574 (Intraocular Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00031733Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaTreatment
NCT00089206Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryTreatment